Research Progress on Natural Plant Molecules in Regulating the Blood–Brain Barrier in Alzheimer’s Disease

Author:

Wu Weidong1,Huang Jiahao2,Han Pengfei3,Zhang Jian1,Wang Yuxin1,Jin Fangfang4,Zhou Yanyan1

Affiliation:

1. Basic Theory of Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin 150040, China

2. Department of Chinese Pharmacology, Heilongjiang University of Chinese Medicine, Harbin 150040, China

3. Science and Education Section, Zhangjiakou First Hospital, Zhangjiakou 075041, China

4. Department of Internal Medicine, Heilongjiang University of Chinese Medicine, Harbin 150040, China

Abstract

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder. With the aging population and the continuous development of risk factors associated with AD, it will impose a significant burden on individuals, families, and society. Currently, commonly used therapeutic drugs such as Cholinesterase inhibitors, N-methyl-D-aspartate antagonists, and multiple AD pathology removal drugs have been shown to have beneficial effects on certain pathological conditions of AD. However, their clinical efficacy is minimal and they are associated with certain adverse reactions. Furthermore, the underlying pathological mechanism of AD remains unclear, posing a challenge for drug development. In contrast, natural plant molecules, widely available, offer multiple targeting pathways and demonstrate inherent advantages in modifying the typical pathologic features of AD by influencing the blood–brain barrier (BBB). We provide a comprehensive review of recent in vivo and in vitro studies on natural plant molecules that impact the BBB in the treatment of AD. Additionally, we analyze their specific mechanisms to offer novel insights for the development of safe and effective targeted drugs as well as guidance for experimental research and the clinical application of drugs for the prevention and treatment of AD.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Heilongjiang Province

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Reference259 articles.

1. Alzheimer disease;Knopman;Nat. Rev. Dis. Primers,2021

2. (2023). 2023 Alzheimer’s Disease Facts and Figures. Alzheimers Dement., 19, 1598–1695. Available online: https://www.google.com.hk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwiYhMLEy8eCAxXraPUHHb1xAekQFnoECBIQAQ&url=https%3A%2F%2Fwww.alz.org%2Fmedia%2Fdocuments%2Falzheimers-facts-and-figures.pdf&usg=AOvVaw2Ly7jeUENko7XcPpRpAMy5&opi=89978449.

3. Epidemiological research progress on Alzheimer’s disease;Wang;Chin. J. Prev. Control. Chronic No-Commun. Dis.,2021

4. Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F.T., and Arab-Tehrany, E. (2022). Alzheimer’s Disease: Treatment Strategies and Their Limitations. Int. J. Mol. Sci., 23.

5. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders;Sweeney;Nat. Rev. Neurol.,2018

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3